Does teplizumab work outside trials? The first real-world signals
At ADA 2026 (reported 9 June 2026) early real-world data suggested 84% of teplizumab-treated people had not progressed to insulin-dependent type 1 at one year.
If you already have Type 1 and inject insulin, teplizumab is not for you, and it helps to know that first. It is the first drug shown to delay Type 1 from developing, and early real-world figures suggest it holds up outside trials, close to what the original studies found.
- Teplizumab is a short course of immune-calming infusions that can push back the day someone needs insulin, given before Type 1 fully arrives.
- Early reports: the first real-world results are beginning to appear and broadly line up with the trials, though the groups are small and firm numbers are not yet established.
- It is for people caught at an early, pre-insulin stage, usually relatives found through screening, and it delays rather than prevents.
- If you already live with Type 1, this matters most for your relatives, who share some of your risk and could be screened.
What real-world means here
Trials are tidy: carefully chosen people, close monitoring, strict rules. Real-world data is what happens when a drug is used in ordinary clinics with ordinary patients, and it matters because a result can look great in a trial and then disappoint in practice. Early reports are only just starting to come through, and so far they broadly line up with what the trials predicted, with teplizumab behaving much as it did in the studies. It is genuinely early, though: the groups are small, the follow-up is short, and firm numbers are not yet established, so this is best read as an encouraging signal rather than a settled result. It is still reassuring for a drug only recently licensed in the UK, where the medicines regulator, the MHRA, approved it in August 2025, though a licence is not the same as routine NHS availability. The picture will firm up as more people are treated and followed for longer.
Who this is actually for
This is the part that gets lost in headlines. Teplizumab does not reverse established Type 1, and it does not help someone already injecting insulin. It is aimed at people found in the early, silent stages, most often the children, brothers, sisters or parents of someone who already has Type 1, because they carry a higher chance of developing it. A blood test for autoantibodies (immune markers that show the process has started) is how those people are spotted. For them, a delay of about two years on average, sometimes longer, can mean more time before insulin, and time to prepare. For you, the reader with Type 1, the useful takeaway is usually about the people around you, not a change to your own treatment.